Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1015550 in idiopathic pulmonary fibrosis
NCT03422068Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing 18 mg BI 1015550 with Placebo (2 arms). Primary endpoint: Percentage of Participants With Drug-related Adverse Events up to 91 days. Started Mar 2018; status: completed.
02
Drugs
nerandomilast
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03422068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03422068.